Detalhe da pesquisa
1.
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Nature
; 535(7610): 148-52, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27362227
2.
VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization.
Proc Natl Acad Sci U S A
; 108(38): 16002-7, 2011 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21911392
3.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Eur J Cancer
; 196: 113458, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039779
4.
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
J Med Chem
; 67(2): 1447-1459, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38198520
5.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
J Clin Oncol
; 41(14): 2651-2660, 2023 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947734
6.
Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
Proc Natl Acad Sci U S A
; 105(39): 15040-5, 2008 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-18818312
7.
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Clin Cancer Res
; 27(7): 2061-2073, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355204
8.
Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
J Med Chem
; 63(5): 2013-2027, 2020 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31059256
9.
JAM-A is present in mammalian spermatozoa where it is essential for normal motility.
Dev Biol
; 313(1): 246-55, 2008 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18022613
10.
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma.
Cancers (Basel)
; 11(6)2019 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146482
11.
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Cancer Res
; 78(6): 1537-1548, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29343524
12.
Deletion of JAM-A causes morphological defects in the corneal epithelium.
Int J Biochem Cell Biol
; 39(3): 576-85, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17118692
13.
Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice.
Arterioscler Thromb Vasc Biol
; 26(9): 2005-11, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16809549
14.
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
J Med Chem
; 60(12): 4869-4881, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28557458
15.
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
Cancer Cell
; 29(4): 574-586, 2016 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27070704
16.
Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2.
Cell Rep
; 10(7): 1066-81, 2015 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25704811
17.
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Mol Cancer Ther
; 14(10): 2249-59, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26206331
18.
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Nat Med
; 21(5): 440-8, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25849130
19.
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Cancer Res
; 74(12): 3294-305, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24747911
20.
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Nat Med
; 20(1): 87-92, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362935